智飞生物：子公司德谷门冬双胰岛素注射液在有效性和安全性上与原研药诺和佳相当

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has completed the Phase III clinical trial summary report for the insulin injection CA508, demonstrating comparable efficacy and safety to the original drug, NovoRapid® [1] Group 1: Clinical Trial Results - The CA508 insulin injection has shown effectiveness and safety comparable to the original NovoRapid® insulin injection [1] - The clinical trial design meets the requirements outlined in the "Guidelines for Clinical Trials of Diabetes Drugs and Biological Products" regarding efficacy and safety evaluation [1] Group 2: Market Context - As of the announcement date, there is only one other domestic company that has received approval for a similar insulin injection product [1]